Introduction
A reciprocal translocation between the long arms of chromosomes 8 and 21, t(8;21)(q22;q22) is one of the most common genetic abnormalities in patients with acute myelocytic leukemia (AML), and is demonstrated in M2 in the French-American-British (FAB) classification. [1] [2] [3] Although t(8;21)AML cells are well known to manifest marked neutrophilic differentiation often with eosinophilia, 4 they strongly express the hematopoietic stem cell-associated antigens CD34, HLA-DR, and MDR1. 5, 6 The breakpoint region genes of 8;21 translocation have been isolated, [7] [8] [9] [10] and were named MTG8(ETO) and AML1, respectively. The AML1 gene shows strong homology with the Drosophila segmentation gene, runt, and the product acts as a transcriptional factor for growth-or differentiationassociated molecules involved in hematopoietic development. 11, 12 Knockout experiments with AML1 show that this factor exerts an effect on early hematopoiesis prior to multiple lineage differentiation. 13, 14 The phenotypic and molecular genetic findings indicate that t(8;21) translocation occurs throughout the process of early hematopoietic development. Thus, the presence of AML1/MTG8 fusion protein is thought to play an important role in the leukemogenesis of t(8;21)AML. Several investigations using transient transfection assays have obtained findings suggesting a relationship between AML1/MTG8 and proliferation-and differentiation-associated molecules such as macrophage colony-stimulating factor receptor (M-CSFR) and BCL-2 in the t(8;21)AML cell lines, 16, 17 The bcl-2 gene was isolated from a follicular lymphoma with t(14;18), 18 and is established as a key molecular regulator of the apoptosis of normal and neoplastic hematopoietic cells. 19 
BCL-2 expression in myeloid cells is commonly strong in CD34
+ cells, and decreases in association with their differentiation. [20] [21] [22] [23] [24] Normal granulocytes and monocytes are very weak or negative for BCL-2. 20 In AML, the relationship between the BCL-2 expression and AML subtypes regarding the differentiation status remains obscure. 20, 21, 23 Klampfer et al 15 recently identified the AML1 binding sequence in a negative regulatory element (NRE) in the bcl-2 gene promoter. The t(8;21) AML cell lines, Kasumi-1 and SKNO-1, express high levels of BCL-2, and AML1/MTG8 activated bcl-2 gene in a monocytic cell line, U937, by transient transfection assay. They concluded that AML-1/MTG8 fusion protein plays an important role for bcl-2 gene activation. Although these two t(8;21) cell lines and de novo t(8;21)AML cells express AML-1/MTG8 fusion protein, there is a distinct difference between these cell lines and AML patients' leukemic cells. It is difficult to promote the in vitro differentiation of Kasumi-1 and SKNO-1 cells with any of the conventional differentiation inducers. However, de novo t(8;21)AML cells are well known to manifest commonly terminal neutrophilic differentiation. Therefore, an investigation of BCL-2 expression in de novo t(8;21)AML is necessary to elucidate the role of AML1/MTG8 in leukemogenesis.
In the present study, we report the BCL-2 expression in de novo t(8;21)AML in relation to the cytokinetics. In contrast to the Kasumi-1 cell line, patients' t(8;21)AML cells showed low levels of BCL-2 expression, with increased numbers of S and G 2 /M cells. Further, DNA binding of AML1/MTG8 fusion protein could not be detected in any of those AML cells.
Materials and methods

Samples and cell lines
Bone marrow (BM) and peripheral blood (PB) smears were prepared for May-Grü nwald-Giemsa, peroxidase, naphthol AS-D chloroacetate esterase, and ␣-naphthyl butylate esterase staining. The morphological diagnosis of AML was made according to FAB classification. The ratio of leukemic cells in all samples was more than 80% morphologically. Normal CD34 + cells in PB were obtained from lymphoma patients in complete remission who were administered granulocyte colony-stimulating factor (G-CSF) for PB stem cell transplantation (PBSCT). All patients gave their informed consent for the procedure involved.
Karyotype analysis
Karyotype analysis was performed on aspirated BM cells, as described previously. 25 
Cell separation
Mononuclear cells (MNC) were separated from heparinized PB and BM by Ficoll-Hypaque centrifugation. Stocked samples, which had been isolated and frozen at −196°C in RPMI1640 medium with 20% heat-inactivated fetal calf serum (FCS) and 10% dimethyl sulfoxide, were also used as needed. MNC in PB from patients primed by G-CSF for PBSCT were suspended with a magnetic bead-coated mouse anti-human CD34 monoclonal antibody (mAb) for 30 min at 4°C. Afer being washed three times with phosphate buffered saline (PBS), CD34
+ fraction was separated with high-gradient magnetic field. The purity of CD34
+ cells was more than 90% by flow cytometric analysis. The anti-CD34 mAb was purchased from Miltenyi Biotec (Bergisch-Gladbach, Germany).
Immunophenotyping and immunostaining of BCL-2
Before immunostaining, MNC were treated with 5% heataggregated human AB serum for blocking of the binding due to receptors for immunoglobulin G (IgG) Fc portion (Fc␥R). CD11b (recognized by Leu15), CD13 (by MCS2), CD15 (by LeuM1), and CD33 (by My9) were tested as myeloid cell markers; CD2 (by Leu5b), CD7 (by TP40), and CD3 (by Leu4) as T cell markers; CD19 (by Leu12 and/or B4), and CD20 (by Leu16) as B cell markers. CD34 (by HPCA-1) and HLA-DR (by anti-HLA-DR) were examined as stem cell markers. Fluorescein isothiocyanate (FITC-conjugated rabbit anti-mouse Ig Fab 2 fraction was used as the second reagent. Samples were examined by a flow cytometer (Cytoron Absolute; Ortho Diagnostic Systems, Tokyo, Japan). We focused on the leukemia cell fraction of the cytogram to clarify its phenotype, as previously described. 5 For the detection of BCL-2, leukemic cells which were stained by phycoerythrin (PE)-conjugated anti-CD34 mAb (PE-HPCA-2) in PBS with 1% heat-inactivated FCS and 0.1% sodium azide (staining buffer) were fixed by PBS with 4% paraformaldehyde (fixation buffer) for 20 min at 4°C. The leukemic cells were washed twice with staining buffer and then treated with FITC-conjugated anti-BCL-2 mAb in PBS with 0.1% saponin (permeabilization buffer) for 20 min at 4°C. The leukemic cells were washed twice with permeabilization buffer, and suspended in staining buffer for a flow cytometer analysis.
At least 5000 cells were examined in the surface marker study. Samples were conventionally considered positive for a mAb if more than 15% of the cells showed immunofluorescence above the control level for surface immunophenotyping. For evaluation of the intensity of BCL-2 expression, the judgment was also performed by relative fluorescence intensity (RFI); RFI = the mean number of FI in log scale of mAb-added sample − the mean number of FI in log scale of the isotype control.
The mAbs TP40 and MCS2 were kindly provided by Drs R Ueda (Nagoya City University, Nagoya, Japan) and E Tatsumi (Kobe University, Kobe, Japan), respectively. The Leu series, HPCA-1, PE-HPCA-2, and anti-HLA-DR mAbs were purchased from Becton Dickinson (Mountain View, CA, USA); My4, My9, and GAM-FITC were from Coulter (Hialeah, FL, USA); FITC-conjugated anti-BCL-2 mAb (M887) was from DAKO Japan (Kyoto, Japan); FITC-conjugated rabbit antimouse Ig Fab 2 fraction and FITC-conjugated goat anti-rabbit Ig Fab 2 fraction were purchased from ZYMED Lab (San Francisco, CA, USA); the whole mouse Igs, IgG 1 , and IgG 2 used as the controls were from Chemicon International (Temecula, CA, USA); the affinity-purified rabbit Ig used as a control was from DAKO Japan.
Western blotting
MNC (1 × 10 6 ) from AML samples and cell lines were lysed at 4°C in lysis buffer (1% Triton X-100, 150 mM NaCl, 20 mM HEPES-NaOH (pH 7.3), 5 mM EDTA, 5 mM NaF, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, 1 mM N-tosyllysine chloromethyl ketone). The lysates were cleared by centrifugation. Cell lysates were subjected to 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and electrotransferred to a polyvinylidene difuluoride (PVDF) microporous membrane (Immobilon PVDF, Millipore, Bedford, MA, USA) which then was incubated with 5% dehydrated milk in PBS containing 0.1% Tween 20 (T-PBS) for 2 h at room temperature. After incubation the membrane was washed three times with the T-PBS for 10 min and incubated with mouse monoclonal anti-BCL-2 (M887) and rabbit polyclonal Abs specific for BCL-X, or BAX for 1 h at room temperature, then washed three times and incubated with horseradish peroxidase-conjugated anti-rabbit IgG (Amersham, Japan) for 1 h. After a further washing, the membrane was incubated with enhanced chemiluminescence substrate solution, and exposed to Fuji RX-U Film (Fuji Photo Film, Tokyo, Japan). Anti-BCL-2 mAb (M887) was from DAKO Japan; Rabbit anti-BCL-X polyclonal antibody (A3535) was from DAKO Japan; rabbit-anti-BAX polyclonal antibody (N-20) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). After transfer, the gel was stained with Coomassie blue to confirm equal loading of proteins in all lanes.
Cell-cycle analysis
A cell-cycle analysis was performed using a CELL CYCLE Test DNA reagent kit (Becton Dickinson). A sample of 5 × 10 5 cells was reacted with 250 l of trypsin buffer for 10 min at room temperature, and then with 200 l trypsin inhibitor and RNase buffer for 10 min at room temperature. The samples were stained by propidium iodide stain solution for 10 min at 4°C, and then analyzed by a flow cytometer (Cytoron Absolute). DNA histograms were analyzed using CELL CYCLE PRO software (Ortho Diagnostic Systems) to determine the distribution of cells in the G 0 /G 1 , S, and G 2 +M phases of the cell cycle.
Cell culture
For the detection of the apoptotic cell death of leukemic cells in liquid culture, leukemic cells freshly isolated were adjusted to a concentration of 2 × 10 6 /ml and then cultured in with FCS-free RPMI 1640 medium at 37°C in a CO 2 incubator for 12 and 24 h. The 3 H-TdR incorporation assay using 5 × 10 4 leukemic cells in RPMI 1640 supplemented with 10% FCS was performed to examine the autonomous DNA synthesis in leukemic cells for 72 h, as previously described. 26 Leukemic cell growth in response to various kinds of growth factors was also tested by an in vitro colony assay, as previously described. 27 Leukemic cells were suspended in Iscove's modified Dulbecco's medium (IMDM) with methylcellulose, 60% heat-inactivated FCS, 1% bovine serum albumin, and 1 × 10 −4 mol/l 2-mercaptoethanol; the suspension was then adjusted to a concentration of 2 × 10 5 cells/ml. Five hundred l of the cell suspension and an equal volume of each growth factor in IMDM were cultured in a 96-well flat bottom microwell culture plate (Nunc, Roskilde, Denmark) at 37°C in a CO 2 incubator for 8 days. A cell suspension without growth factors was used as a control. The number of colonies (more than 20 cells) was counted under an inverted microscope. G-CSF, interleukin-3 (IL-3) and GM-CSF were used at a concentration of 10 ng/ml, and IL-5 was used at a concentration of 1 g/ml. Granulocyte colony-stimulating factor (G-CSF), interleukin-3 (IL-3) and granulocyte-macrophage colonystimulating factor (GM-CSF) were kindly provided from Kirin Co (Tokyo), and IL-5 was purchasd from R&D Systems (Minneapolis, MN, USA).
Preparation of whole cell/nuclear extracts and electrophoretic mobility-shift assay (EMSA)
Whole-cell extracts were prepared from BM samples, as previously described. 28 The double-stranded oligonucleotide probes for used the EMSA were as follows; the wild-type AML1 binding site in the NRE of bcl-2 gene;
15 5′-TCCCCACCCCTCGCCGCACCACACACAGCGCGGGCTTCT-3′. The mutated AML1 binding site: 5′-TCCC-CACCCCTCGCCGCAGTCTGCACAGCGCGGGCT-3′.
The cyclic AMP-responsive element binding protein (CREB) binding site of the wild-type in bcl-2 gene promoter:
29 5′-GTTGAACGTGTGACGTTACGCA-3′. The mutated 1 CREB binding site: 5′-GTTGAAAGTGTGACGTTACGCA-3′. The mutated 2 CREB binding site: 5′-GTTGAACGTG TGAATTTACGCA-3′. The probes were labeled with ␣ 32 PdCTP. A total of 20 000 c.p.m. of probe was incubated with 10 g of whole-cell or nuclear extract in 20 l containing a final concentration of 20 mmol/l HEPES (pH 7.9), 50 mmol/l KCL, 2 mmol/l MgCl 2 , 1 mmol/l EDTA, 1 mmol/l dithiothreitol, 50 mg/ml polydeoxyisosinic-deoxycytidylic acid, 0.1 mg/l bovine serum albumin, and 10% (vol/vol) glycerol on ice for 20 min. For a supershift analysis, samples were incubated with mouse anti-CREB1 monoclonal Ab (24H4B) and mouse anti-ATF-2 mAb(F2BR-1): Santa Cruz Biotechnology, for 30 min on ice before the addition of labeled probes. In addition, 100-fold unlabeled probes were added to extracts as a competitor, and the extracts were incubated for 30 min with labeled probes. For the determination of the phosphorylation status of DNA binding protein, 0.05 U of potato acid phosphatase (Sigma, St Louis, MO, USA) was added to the extracts for 30 min at room temperature before the addition of the labeled probe, as previously described. 30 
Statistical analysis
Differences among subtypes of AML were evaluated by the 2 test or by t-test. The statistical analyses were performed with the STATISTICA software program.
Results
Cellular characteristics of AML cells
The patient groups consisted of 13 M1, 29 M2, 11 M3, 12 M4, and nine M5 patients. The samples of 46 of these 74 patients were positive for CD34. The t(8;21) abnormality was observed in 17 patients, the t(15;17) abnormality in 11, various other types of abnormalities in 23, and a normal karyotype in 22. Chromosome of the remaining one patient was not examined. All cases with t(8;21) were classified as AML.M2 showing granulocytic maturation, and the blastic cells were positive for CD34. All of the M1 samples were positive for CD34, and two of the nine M5 samples were positive for CD34.
BCL-2 expression in AML cells by direct immunofluorescence
BCL-2 expression was detected in all of the 74 AML samples by direct immunofluorescence, and the fluorescence intensity found to correspond well to the signals in the Western blot study (Figures 1 and 2a) . The RFI of BCL-2 expression in the + AML samples without t(8;21) was 70.3 ± 36.4, significantly higher than that of the t(8;21) AML samples (P Ͻ 0.01; Figure 3a) . Figure 3b shows the relationship between BCL-2 expression and the FAB subtypes. The RFI of BCL-2 in t(8;21) was lower than that in M1 (81.1 ± 44.9), M2 without t(8;21) (66.4 ± 31.3), M3 (77.5 ± 21.9), M4 (49.5 ± 22.2), and M5 (43.8 ± 25.0).
In t(8;21)AML, leukemic cells consist of a heterogeneous population showing blastic to mature granulocytic features. Most of the leukemic cells in granulocytic fraction were negative for CD34. 5 As shown in Figure 4 , the RFI of BCL-2 in the CD34 − fraction in t(8;21)AML was not significantly different from that in the CD34 + fraction. The RFI of BCL-2 in Kasumi-1 cells (RFI = 91.4) was higher than that in freshly isolated t(8;21) samples ( Figure 5 ). The expression level of BCL-2 in t(8;21)AML samples was similar to those of normal CD34 + myeloid cells primed with G-CSF for PBSCT (RFI = 28.7), neutrophils (RFI = 28.5), and monocytes.
Western blotting analysis of long sized BCL-X (BCL-X L ) and BAX
The BCL-X L expression, in the AML with granulocytic differentiation such as t(8;21) AML and AML M3, were lower than other types of the AML, such as AML M1 or AML M5. The small sized Bcl-X (BCL-Xs) was not detected in any sample examined. There were no significant differences in the expression of BAX between t(8;21) AML samples and other types of AML samples (Figure 2b and c) .
Cytokinetic analysis of t(8;21) AML cells
A cytokinetic analysis could be performed for 67 AML samples; 16 of t(8;21)AML, 11 of M1, 12 of M2 without t(8;21), 10 of M3, nine of M4, and nine of M5. The BCL-2 expression level and S/G 2 /M population in AML samples showed a significant inverse correlation (r = −0.5381) ( Figure 6) . The S/G 2 /M population in the t(8;.21)AML (11.5% ± 3.7%; mean ± 1 s.d.) was significantly larger than that in the other types of AML (6.3% ± 5.6%) (P Ͻ 0.01), and was larger than that in the CD34 + AML without t(8;21) (6.1% ± 6.1%) (Figure 3c) . The S/G 2 /M population in t(8;21)AML was also larger than that in M1 (2.7% ± 3.4%), non-t(8;21) M2 (5.4% ± 5.6%), M3 (5.9% ± 2.1%), and M4 (8.9% ± 5.0%) (Figure 3d ). There was no significant difference of S/G 2 /M population between t(8;21) AML and M5 (11.6% ± 7.0%).
Apoptotic cell death and autonomous DNA synthesis in t(8;21) AML cells
Three t(8;21) samples and five CD34
+ non-t(8;21)AML samples were used for the detection of apoptotic cell death. The sub-G1 DNA content in the t(8;21)AML was 28.3% ± 12.8% after the 12-h culture and 49.5% ± 15.4% after the 24-h culture, while that in the CD34 + non-t(8;21)AML was 13.2% ± 4.8% after the 12-h culture and 23.3% ± 6.0% after the 24-h culture (Figure 7 ). The differences of sub-G1 DNA content between the t(8;21)AML and CD34 + nont(8;21)AML samples were significant (P Ͻ 0.05 in the 12-h culture, and P Ͻ 0.02 in the 24-h culture).
Nine t(8;21)AML and 48 non-t(8;21)AML (11 M1, 13 M2, nine M3, nine M4, and six M5) samples were examined for autonomous DNA synthesis. 
Leukemic colony formation of t(8;21) AML cells
A leukemic colony assay was performed for nine t(8;21)AML, 13 CD34
+ non-t(8;21)AML, and 15 CD34 − non-t(8;21)AML samples. The colony number of the t(8;21)AML cells in the culture with either IL-3 (8.0 ± 4.2; mean ± 1 s.e.) or GM-CSF (6.4 ± 4.2) were significantly lower than that of CD34 + nont(8;21)AML (25.7 ± 6.0 with IL-3 and 45.3 ± 9.8 with GM-CSF) ( Figure 9 ). The IL-3-or GM-CSF-induced colony formation in 
CD34
− non-t(8;21)AML (19.0 ± 4.1; 25.5 ± 8.7) was prominent in comparison with those in t(8;21) AML cells, but the differences were not significant. In contrast, the number of IL-5-induced colonies in t(8;21)AML (12.1 ± 5.0) was significantly higher than that in both CD34 + non-t(8;21)AML (3.0 ± 1.3) and CD34
− non-t(8;21)AML (2.6 ± 5.4). There were no significant differences in the G-CSF-induced colony formation among t(8;21)AML (46.9 ± 11.6), CD34
+ non-t(8;21)AML (49.0 ± 12.0) and CD34 − non-t(8;21)AML (59.8 ± 13.7).
DNA binding of AML1/MTG8 and CREB1 inBCL-2 promoter
Whole-cell extracts from Kasumi-1 bound the AML1 binding site in bcl-2 gene promoter NRE, but none of whole-cell extracts from freshly isolated t(8;21)AML did so (Figure 10a ). The DNA binding activity of cellular extracts from Kasumi-1 decreased after treatment with potato acid phosphatase (Figure 10b ). With the treatment using the CRE site in the bcl-2 gene promoter, four bands were detected by using wholecell extract from Kasumi-1; two of them disappeared and a new slowly migrating band emerged with the use of anti-CREB1 Ab. However, none of the cellular extracts from de novo AML including t(8;21) AML bound to the CRE site ( Figure 11 ).
Discussion
In this study, we demonstrated the BCL-2 expression in t(8;21)AML by flow cytometry together with a Western blot study. The BCL-2 expression in this type of AML was significantly lower than that in other types of AML. In previous reports, the expression level of BCL-2 in AML varies from case to case, and the relationship between BCL-2 expression and FAB subtype was unclear. The data presented here demonstrate that AML.M1 and M3 exhibiting marked morphological In normal hematopoiesis, several reports have pointed out that CD34
+ myeloid precursors express high levels of BCL-2 in comparison with mature granulocytes and monocytes. 20, 21, 23 In AML, Bradbury et al also described that the CD34 + fraction expressed higher levels of BCL-2 than did the CD34 − fraction. CD34 + cells consist of stem cells at the various stages in hematopoiesis. Park et al recently clarified that BCL-2 expression in the most primitive precursors in human hematopoiesis, ie small-to medium lymphocyte-sized CD34 + lineage (lin)
− cells, was absent or much lower than that in CD34 + lin − blast-sized cells which are thought to be more differentiated progenitors. 22 Blastic cells in t(8;21)AML are CD34 high CD33 low , 5 and show a weaker expression of LFA-1 compared to other types of AML cells (data not shown). This phenotype is similar to that of primitive myeloid precursors. 31, 32 The manner of BCL-2 expression in t(8;21)AML cells is therefore thought to be comparable to that in primitive myeloid precursors. Indeed, the expression level of BCL-2 in the CD34
+ and CD34 − fractions of t(8;21)AML cells was almost the same as that in normal CD34
+ cells primed by G-CSF, which are considered to correspond to primitive hematopoietic precursors. 33, 34 Sanz et al 35 reported that BCL-X is downregulated when CD34 + cells are differentiated toward mature granulocytes, whereas it is upregulated toward monocytes/macrophages. In this study, the expression level of BCL-X L in t(8;21) AML was lower than that of other types of AML, while there are no significant difference between the t(8;21)AML and non-
Figure 6
The inverse relationship between BCL-2 expression and S/G 2 /M population in AML. The correlation was inverse and significant (P Ͻ 0.01). Each data point indicates individual patient (n = 67). These findings indicate that the BCL-2 expression in t(8;21)AML cells including the differentiated cells was intrinsically fixed at a low level, ie the same level of the most primitive hematopoietic precursors; the results also suggest that t(8;21)AML cells are more apt to enter the process of apoptosis in comparison with non-t(8;21)AML cells.
BCL-2 has been suspected to be a major regulator of a homeostatic balance between cell survival and cell death. Recent reports have provided some evidence that BCL-2 exerts its effect on a cell-cycle point at the G 0 or G 1 to S phase transition and can slow cell proliferation in both lymphocytes and myeloid cells. [36] [37] [38] Indeed the S/G 2 /M population in the present t(8;21)AML samples was larger than that in the other subtypes of AML except AML.M5, indicating a marked cellcycle progression in t(8;21)AML. Further, in t(8;21)AML, spontaneous apoptosis after 12-and 24-h liquid cultures was prominent, and the autonomous DNA synthesis after a 72-h liquid culture was low. Thus the t(8;21)AML cells easily die by apoptosis, in vitro.
The low level of BCL-2 in t(8;21)AML is thought to hasten their apoptotic death, although the leukemic cells differentiate into mature neutrophils in vivo. Some exogenous factors thus seem to be required for the terminal differentiation. Several cytokines are considered as survival factors at terminal differentiation in association with BCL-2 expression.
39-42 G-CSF triggers the proliferation of cell-cycle-dormant myeloid progenitors, and exerts an effect on the proliferation and differentiation of monopotent neutrophil progenitors. 43 Eosinophilia is one of the characteristic blood pictures of t(8;21)AML, and the in vitro eosinophilic differentiation of the leukemic cells induced by IL-5 was also reported. 16, 44 Ema et al 16 reported that IL-5 was able to support the survival of t(8;21)AML cells for more than 4 weeks. Our study indicated that G-CSF and IL-5 were able to promote predominant colony formation of t(8;21)AML cells. The present results and previous reports suggest that G-CSF and IL-5 are able to support the survival and differentiation of t(8;21)AML cells. Common receptor ␤ chain (commonR␤) is shared by GM-CSF receptor ␣ chain (GM-CSFR␣), IL-3 receptor ␣ chain (IL-3R␣), and IL-5 receptor ␣ chain (IL-5R␣) for their signal transduction. 45, 46 The poor responsiveness of t(8;21)AML cells to IL-3 and GM-CSF leads us to speculate that the eosinophilic differentiation, but not monocytic differentiation observed in t(8;21) AML, might be the result of an advantage of the IL-5R␣ transduction system over those of the IL-3R␣ and GM-CSFR␣ transduction system. There are some reports that in bcl-2-transfected multipotent hematopoietic cell lines, upon cytokine withdrawal, have been shown to multilineage differentiation. 47 In our study of t(8;21)AML cells, however, low BCL-2 expression and prominent granulocytic and eosinophilic differentiation were observed. The relationship between BCL-2 expression and Colony formation of t( 29 Gubina et al 48 found that the overexpression of protein kinase C (PKC) induced BCL-2 expression in the human AML cell line TF-1. These findings suggests that the CREB proteins activated by PKC are important transactivators of the bcl-2 gene. In the present study, the cellular extract from Kasumi-1 cells bound the CRE site in the bcl-2 gene promoter, whereas none of the cellular extracts from any de novo AML including t(8;21)AML did so. AML1 was shown to be phosphorylated by an extracellular signal-regulated kinase. 49 Our present results indicate that the DNA binding activity of transactivators in de 
Figure 11
EMSA of the bcl-2 promoter CRE site. Whole-cell extracts from Kasumi-1 and de novo AML (lanes 1-9) were bound to the CRE site in the bcl-2 promoter. Cellular extracts from Kasumi-1 showed four bands bound to the CRE site. With the addition of anti-CREB1 Ab, two bands disappeared and a new slowly migrating band emerged (supershift). The extracts from de novo AML showed no significant bands bound to the CRE site. 1, 2, t(8;21) AML; 3, AML M1; 4, 5, M2 without t(8;21) AML; 6, AML M3; 7, 8, AML M4; 9, AML M5. novo t(8;21)AML cells is different from that in Kasumi-1 cells due to the activation manner of several phosphorylation pathways.
The AML1/MTG8 fusion protein may be responsible for the formation of cellular characteristics of t(8;21)AML probably including the BCL-2 regulation and terminal differentiation of the leukemic cells. Further investigations of the bcl-2 gene regulation system are necessary to clarify the precise relationship between the BCL-2 expression level and the presence of AML1/MTG8 fusion protein.
